Abstract
If clinical trials were sporting contests, then it would be fair to say that low-dose aspirin plus extended-release dipyridamole (Aggrenox) was the clear favorite against clopidogrel going into the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial (ClinicalTrials.gov number, NCT00153062). The trial, reported on in this issue of the Journal by Sacco et al.,1 tested these two antiplatelet agents for secondary stroke prevention in their first head-to-head contest. In two previous large randomized clinical trials enrolling patients after stroke (the European Stroke Prevention Study 2 [ESPS2]2 and the European/Australasian Stroke Prevention in Reversible Ischemia Trial3 [ESPRIT, NCT00161070]), low-dose aspirin . . .
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
